ABC | Volume 113, Nº2, August 2019

Short Editorial Askin et al. Subclinical LVDD in Type 2 DM Arq Bras Cardiol. 2019; 113(2):216-217 1. TeiC,NishimuraRA,SewardJB,TajikAJ.NoninvasiveDoppler-derivedmyocardial performance index: correlation with simultaneous measurements of cardiac catheterizationmeasurements.JAmSocEchocardiogr,1997;10(2):169–78. 2. Mishra RK, Kizer JR, Palmieri V, Roman MJ, Galloway JM, Fabsitz RR, et al. Utility of the myocardial performance index in a population with high prevalences of obesity, diabetes, and hypertension: the strong heart study. Echocardiography. 2007;24(4):340-7. 3. Carluccio E, Biagioli P, Alunni G, Murrone A, Zuchi C, Biscottini E, et al. Improvement of myocardial performance (Tei) index closely reflects intrinsic improvement of cardiac function: assessment in revascularized hibernating myocardium. Echocardiography. 2012;29(3):298-306. 4. Askin L, Cetin M, Tasolar H, Akturk E. Left ventricular myocardial performance index in prediabetic patients without coronary artery disease. Echocardiography. 2018;35(4):445-9. 5. Mittal SR, Pancholi N. Left ventricular outflow tract presystolic flowvelocity – another marker of left ventricular diastolic function. Int J Cardiovasc Imaging. 2002;18(4)249-56. 6. Korkmaz L, Akyüz AR, Gurbak I, ErkanH, Dursun I, Celik S, et al. Presystolic Awavemay predict increased arterial stiffness in asymptomatic individuals. Blood Press Monit. 2016;21(3):144-8. 7. Kul S, Dursun I, Ayhan S, Sayin MR, Uçuncu O, Bulbul NE, et al. Presystolic Wave is Associated with Subclinical Left Ventricular Dysfunction Assessed by Myocardial Performance Index in Type 2 Diabetes Mellitus. Arq Bras Cardiol. 2019; 113(2):207-215 8. StahrenbergR,EdelmannF,MendeM,KockskämperA,DüngenHD,Scherer M, et al. Association of glucosemetabolismwith diastolic function along the diabetic continuum. Diabetologia. 2010;53(7):1331–40. 9. de Simone G, Devereux RB, Chinali M, Lee ET, Galloway JM, Barac A, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens. 2010;28(7):353–60. 10. Litwin SE. Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy? Diabetes. 2013;62(10):3329–30. 11. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: a review. Diabetologia. 2001;44(2):129-46 12. Bojunga J, Nowak D, Mitrou PS, Hoelzer D, Zeuzem S, Chow KU. Antioxidative treatment prevents activation of death-receptor and mitochondrion-dependent apoptosis in the hearts of diabetic rats. Diabetologia 2004;47(12):2072-80. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 217